CRISPR technology is transforming modern medicine by enabling precise DNA editing to treat genetic disorders, including sickle cell anemia and beta-thalassemia, experts say.
CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, was initially discovered as part of a bacterial defense system.
Scientists have since repurposed it into a powerful gene-editing tool that uses a Cas nuclease enzyme guided by programmable RNA to make highly accurate cuts in DNA, allowing precise genetic modifications at specific points in the genome.
According to the US National Institutes of Health (NIH), CRISPR/Cas9 is revolutionizing biomedical research by providing a fast, affordable, and highly precise method to correct genetic errors and regulate genes in cells and organisms. Its simplicity, efficiency, and broad applications are reshaping how medicine addresses genetic disorders, cancers, and rare diseases.
Since 2019, CRISPR therapies have transitioned from laboratory research to clinical use. In a milestone development, Victoria Grey became the first patient to receive CRISPR treatment for sickle cell disease (SCD), resulting in a cure that eliminated her painful crises, according to NPR.
In December 2023, the US Food and Drug Administration (FDA) approved Casgevy (exagamglogene autotemcel), marking the world’s first CRISPR-based therapy for SCD and beta-thalassemia.
The treatment uses edited haematopoietic stem cells to reactivate foetal haemoglobin, according to Harvard Medical School.
Clinical advancements have continued, with new lipid nanoparticle (LNP) delivery systems developed by companies like Intellia showing early success in vivo gene editing, targeting the liver and other tissues, according to CRISPR Medicine News.
A landmark case earlier this year involved a six-month-old child with CPS1 deficiency that was treated with personalised CRISPR base editing using LNPs. The treatment significantly improved his condition, eliminating the need for a liver transplant, according to The Sun.
Despite these advances, challenges persist. Scientists remain concerned about the possibility of off-target genetic edits, though machine-learning models are being developed to predict and reduce such risks. Additionally, improving delivery systems and scaling up treatments for complex diseases remain key areas of focus, according to the journal Nature.
CRISPR has become the most accessible and versatile gene-editing tool, outpacing earlier technologies due to its RNA-guided simplicity. As delivery methods improve and immune responses are better managed, CRISPR's potential is expanding beyond rare genetic disorders to treating cancers, metabolic diseases, and possibly even trisomy-21 through chromosome-specific editing.
In summary, CRISPR has already reshaped modern medicine — delivering historic cures in haematology, pioneering in vivo editing techniques, and leading the development of personalised therapies.
Experts believe that with continued advances in precision, safety, and delivery, CRISPR-driven treatments will redefine patient care for years to come.
BP English/ARK
